Joseph Kim exploring GPCR structural biology, cryo-electron microscopy, opioid receptor pharmacology, Joseph Kim is a structural biologist studying membrane proteins and GPCR pharmacology. molecular structures inform the design and development of new therapeutics. GPCR Drug Discovery Is Increasingly Structural Modern GPCR drug discovery increasingly integrates structural You could easily imagine separate therapeutic programs targeting those different physiological effects

optimize the design and engineering of more efficacious therapeutics. perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target therapeutics The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and A notable therapeutic is an enzyme that hydrolyzes cocaine. as a treatment for cocaine abuse, a debilitating disease that would require long-term and sustained therapeutic

This conversation covers thermostabilization, cryoEM, and GPCR structural biology. << Back to podcast list Strategic Partner(s) Chris Tate: Thermostabilizing GPCRs for Structural Biology For most of the 1990s and early 2000s, GPCR structural biology was not a biology problem - it was a stability problem GPCR structures is no longer the limiting step in drug discovery. to arrestin and also the first structure of a Class D receptor.

The therapeutic mechanism, however, is inseparable from the psychedelic experience itself, and not every questions in current GPCR pharmacology: can biased signaling at the serotonin 2A receptor decouple the therapeutic What you usually can't do is know which pathway, in which disease, will actually be therapeutic. The premise: psilocybin's therapeutic effect on depression is now well documented, but it is locked to Six weeks in, structures are turning over and chemistry is iterating.

Fiona Marshall on structure-based GPCR drug discovery, the GABA-B heterodimer, the acetate that rewrote routine, the insight that seeded Heptares Therapeutics. She co-founded Heptares Therapeutics and served as Chief Scientific Officer for twelve years, through Structures Reveal Pockets the Field Didn't Know Existed Once GPCR structures became routine, unexpected As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery

Structural biologist Qing Fan describes a decade of GABA-B receptor research at Columbia - from obligate mutations in the GABA-B transmembrane domain and what they suggest about precision pharmacology The therapeutic Fan describes the resolve-the-disease-isoform-structure approach as underutilized: most structural work But its therapeutic window is narrow. puzzles; the cryo-EM structures raised as many mechanistic questions as they answered.

daLUXendin Family Fluorescent dual agonists for both GLP-1R and GIPR (daLUXendin544+ and daLUXendin660+), structurally His work carries direct translational relevance to diabetes and obesity therapeutics. It provides curated industry intelligence, expert-led masterclasses, and structured engagement opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic drug discovery trends and developments Expert-led webinars and masterclasses with leading researchers Structured

His main research group centers on the function, structure, and regulation of G protein-coupled receptors Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics

Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused Kobilka’s lab contributing to the elucidation of high-resolution structures of various GPCRs. Dr. Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Unlock the Full Dr.

development, with 25+ years of expertise and validated cell-based assays spanning basic research through therapeutic It provides curated industry intelligence, expert-led masterclasses, and structured engagement opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic drug discovery trends and developments Expert-led webinars and masterclasses with leading researchers Structured

field of pharmacology and biochemistry of GPCR and the crucial role of the lipidic environment on their structure In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases

development, with 25+ years of expertise and validated cell-based assays spanning basic research through therapeutic It provides curated industry intelligence, expert-led masterclasses, and structured engagement opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic drug discovery trends and developments Expert-led webinars and masterclasses with leading researchers Structured

Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights concentrations, her work highlights why receptor localization and protein complex assembly matter for therapeutic How an integrated training and lab structure at Monash Institute of Pharmaceutical Sciences fosters innovation localized signaling events, how these mechanisms are hijacked in disease, and how they can be leveraged for therapeutic

Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic Operational Discipline I instill structure and consistency across every phase of your discovery process Yamina brings the clarity, rigor, and structured decision-making that keeps programs on track. Abishek Iyer, CEO Ashta Therapeutics Before working with Yamina, we had solid internal momentum but needed Her input helped us structure the screening funnel, define clear go/no-go criteria, and integrate ADME

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics rerouted his path toward a breakthrough GPCR research career The inside story behind founding Blue Therapeutics Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics discovery, he later co-founded Superluminal Medicines, a company using machine learning to explore GPCR structure-function

Her work involves the pharmacological and structural characterisation of novel putative antipsychotic molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics

Your One-Stop-Shop for GPCR Drug Discovery and Development Researchers developing GPCR-targeted therapeutics expertise and provides you with product solutions including cell-based assays for basic research through therapeutic Principle of Eurofins DiscoverX Cell-based Assays Whether you are developing small-molecule or biologic therapeutic Explore GLP-1 Product Solutions to Support Obesity/Diabetes See GLP-1 Solutions Accelerating Obesity Therapeutics These GPCRs are excellent for use in functional, structural, or identification assays.

allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics the relocation of some university labs to facilitate collaboration and overcome the siloed department structure Additionally, they explored the unique culture and structure of their Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic commercialization.

allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics the relocation of some university labs to facilitate collaboration and overcome the siloed department structure Additionally, they explored the unique culture and structure of their Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic commercialization.

Themes of the Conversation Allosteric modulation of opioid receptors - mechanism, selectivity, and therapeutic receptor biology The Field Application Scientist as a career model for GPCR-trained scientists The structural The therapeutic logic is that decoupling from the orthosteric site might preserve pain relief while altering Academia and industry are structurally complementary - not competing versions of the same thing Academia Livingston argues these structural constraints make the two sectors dependent on each other - and notes

This conversation explores the intersection of computational biology, cheminformatics, and structural protein sequence to a pharmacologically characterized receptor with identified ligands, a determined structure He maintains and develops GPCRDB, a continuously updated database and tool platform that integrates structural symptomatic of a deeper challenge: the field has not yet fully characterized which signaling pathways produce therapeutic The result was a structured group management model built around four specialized subgroups, each with

Nicola J Smith is an expert in molecular pharmacology with a track record in exploring GPCR structure-function orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic

allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They explored the evolution of the field, allosteric modulation concepts, and potential therapeutic approaches Arthur will work on designing ligands for specific receptors, aiming to create biased agonists for therapeutic endogenous allosteric ligands and the possibility of using a neutral allosteric ligand as a preferred therapeutic

working with distinct chemical scaffolds like thiazolidines and xanthinediones, Ben is helping define how structurally team aims to understand how and where these compounds interact with the receptor, paving the way for structure-based Structural Biology Roadblocks: The Cryo-EM Challenge One bottleneck in Ben’s work is visualizing binding Still, by collaborating with structural biology teams and combining cryo-EM with NMR , his lab is narrowing Clements' work is primarily focused on translational developments of small molecule therapeutics, and

View Biophysics Biophysical characterization for mechanistic, structure-informed insight. View Protein Production GPCR protein production to support downstream functional and structural work. profiling, selectivity, and promiscuity gpcrMAX orphanMAX Chemokine obesityLITE Peptide Hormone Class B Therapeutic

migraine therapies Obligatory receptor heterodimers and the limits of current characterization tools Structural to produce a distinct complex - different ligand selectivity, different signaling profile, different therapeutic Shared structural features between the two receptor complexes, combined with the known pharmacology of RAMPs Act Allosterically - Not Through Direct Ligand Contact Structural data from the CLR and CTR receptor antibody selectivity, selective ligands, and bimolecular fluorescence complementation in vivo 26:42 Structural

During his master's studies, he specialized in Biomedical Biotechnology and Structural Biology/Biochemistry nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic

Niv describes how bitter taste receptors differ structurally from most other GPCRs - missing conserved activation, and resistant to pharmacological blockade - and why those properties have shaped both the therapeutic training, she built BitterDB - the first dedicated database of bitter compounds - and has mapped the structural Bitter taste receptors are built to activate, not to be blocked Bitter taste GPCRs are structurally unusual Niv's lab is developing a recommendation system - trained on known receptor-ligand pairs and the structural

Anita Nivedha discusses computational approaches to decoding signal propagation within GPCR structures observed signaling outcomes, providing a bridge between structural biology and pharmacology. visualization to become quantitative tools for understanding receptor activation and guiding GPCR-targeted therapeutics ligand bias inside receptor structures? That transmission happens through communication pathways across the receptor structure.

technology platform deciphering cell signaling pathways combined with AI-based approaches to elucidate structure the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.